Congress to investigate FDA's medical device approval process

Share this article:

Reps. John Dingell (D-MI) and Bart Stupak (D-MI) have launched an investigation into the FDA's process for reviewing medical devices.

The investigation was prompted by a letter from “a large group of scientists and physicians” within the FDA's Center for Devices and Radiological Health (CDRH), dated Oct. 14. The letter describes CDRH managers that have “corrupted and interfered with the scientific review of medical devices,” according to a release from the office of Rep. Dingell, chairman of the Committee on Energy and Commerce.

The statement goes on to say that the Committee has been “provided with compelling evidence to support the charges that senior managers within CDRH ‘ordered, intimidated and coerced FDA experts to modify their scientific reviews, conclusions and recommendations in violation of the law.'”

The individuals comprising the group of scientists and physicians at CDRH are being kept anonymous to protect them from additional reprisal and mistreatment, according to the Commitee statement. 

In a letter (found here in pdf format) to FDA commissioner Andrew von Eschenbach—written by Stupak, chairman of the Subcommittee on Oversight and Investigations, and Dingell—the duo cite further allegations made in the CDRH letter: “The CDRH scientists…state that CDRH managers ordered them ‘to make safety and effectiveness determinations that are not in accordance with scientific regulatory requirements, to use unsound evaluation methods, and accept clinical and technical data that is not scientifically valid or obtained in accordance with legal requirements, such as obtaining proper informed consent from human subjects.'"  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...